Drug Profile
MEDI 491
Alternative Names: B19 parvovirus vaccine; Recombinant baculovirus-expressed B19 parvovirus virus-like particle vaccine - AstraZeneca/NHLBI; Recombinant baculovirus-expressed B19 parvovirus VLP vaccine - AstraZeneca/NHLBILatest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator National Heart, Lung and Blood Institute; National Institutes of Health (USA)
- Developer Chiron Corporation; MedImmune; National Institutes of Health (USA)
- Class Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parvovirus infections